Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2010 1
2012 2
2013 1
2015 1
2017 1
2019 2
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Hummel HD, et al. Among authors: boix o. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Immunotherapy. 2021. PMID: 33172323 Free article.
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. Atrafi F, et al. Among authors: boix o. Clin Cancer Res. 2021 Dec 1;27(23):6366-6375. doi: 10.1158/1078-0432.CCR-20-4185. Epub 2021 Sep 13. Clin Cancer Res. 2021. PMID: 34518310
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Schneeweiss A, et al. Among authors: boix o. Cancers (Basel). 2019 Dec 10;11(12):1987. doi: 10.3390/cancers11121987. Cancers (Basel). 2019. PMID: 31835495 Free PMC article.
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Strumberg D, et al. Among authors: boix o. Br J Cancer. 2012 May 22;106(11):1722-7. doi: 10.1038/bjc.2012.153. Epub 2012 May 8. Br J Cancer. 2012. PMID: 22568966 Free PMC article. Clinical Trial.
Tacrolimus/cerivastatin interaction study in liver transplant recipients.
Mück W, Neal DA, Boix O, Voith B, Hasan R, Alexander GJ. Mück W, et al. Among authors: boix o. Br J Clin Pharmacol. 2001 Aug;52(2):213-5. doi: 10.1046/j.0306-5251.2001.01424.x. Br J Clin Pharmacol. 2001. PMID: 11488782 Free PMC article. Clinical Trial. No abstract available.
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB. Schultheis B, et al. Among authors: boix o. Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13. Ann Oncol. 2013. PMID: 23493136 Free PMC article. Clinical Trial.
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O. Mross K, et al. Among authors: boix o. Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15. Clin Cancer Res. 2012. PMID: 22421192 Free article. Clinical Trial.
12 results